clinical trial · NCT05909436
Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
Guangzhou Gloria Biosciences Co., Ltd.·phase2·recruiting·n = 107
Solid TumorGLS-012GLS-010
brief summary
This is a phase I/II study to investigate the safety, tolerability, and preliminary efficacy of GLS-012 monotherapy and in combination with GLS-010 in subjects with advanced solid rumor after progression on standard treatment.
started
Oct 31, 2022
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Jun 18, 2023
official title
A Phase I/II Study Evaluating the Safety, Tolerability and Preliminary Efficacy of GLS-012 Monotherapy and in Combination With GLS-010 in Patients With Advanced Solid Tumors After Progression on Standard Treatment (Triumph-01)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol